Full history for every metric is available with a Kvantra account

Stock profile
Immunovant, Inc. logo

Immunovant, Inc. (IMVT)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
6.57B
Currency USD
KvantraRankAbout52
IValue48
IIQuality42
IIIMomentum72
Current price
31.77 USD-2.31%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
2020202120222023202420252026TTM
Total revenue$m0.000.000.000.000.000.000.007.10
Operating profit$m-533-531
Net profit$m-66-107-157-211-259-414-506-509
EPS reported$-2.77-2.56
Operating cashflow per share$-2.23-1.91
Capex per share$0.000.00
FCF per share$-2.23-1.91
Free cash flow$m-407-395
Net debt$m-902-722
Book value equity$m853657
Book value per share$4.673.18
Number of sharesm182.42206.67
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
2020202120222023202420252026TTM
Value
P/E TTMx--
P/B LTMx5.3110.01
P/S LTMx0.00926.67
P/FCF LTMx-11.12-16.64
EV/EBITDA LTMx-7.19-11.48
EV/Sales LTMx0.00824.87
Earnings Yield LTM%-11.16%-7.42%
FCF Yield%-8.99%-6.01%
Quality
ROE%-59.30%-63.01%
ROIC%-62.50%-80.67%
Operating margin%0.00%-7488.4%
Gross margin%0.00%100.00%
FCF/Sales%--5567.5%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%--
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx-5,657.19-
Net Debt/EBITDAx1.791.42
EBIT/Net interestx--
Net debt/market cap%-19.91%-10.99%
Net debt/Equityx-1.06-1.10
Gross debt/equityx0.000.00

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price31.77 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Immunovant, Inc. (IMVT)

IMVT · NASDAQ · Healthcare
31.77 USD-2.31%
Sign up to track this stock
Benchmarks
KvantraRank52
Market cap6.57B
P/E NTMN/A
P/E TTMN/A
KvantraRank?52 / 100
Value
48
Quality
42
Momentum
72
Financialsin USD
20252026TTM
Analyst target
Consensus
Current31.77 USD
Upside
Price consensus
Last year average price target
Current price31.77 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free